ZOMDF — Zomedica Income Statement
0.000.00%
Last trade - 00:00- $52.92m
- -$18.44m
- $27.29m
- 56
- 55
- 21
- 40
Annual income statement for Zomedica, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 4.13 | 18.9 | 25.2 | 27.3 |
| Cost of Revenue | |||||
| Gross Profit | — | 3.05 | 13.7 | 17.3 | 19.1 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 16.8 | 25 | 40.9 | 68.5 | 78.3 |
| Operating Profit | -16.8 | -20.8 | -21.9 | -43.3 | -51.1 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -16.9 | -20.7 | -19.4 | -35.9 | -47.5 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -16.9 | -18.4 | -17 | -34.5 | -47 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -16.9 | -18.4 | -17 | -34.5 | -47 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -16.9 | -18.4 | -17 | -34.5 | -47 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.046 | -0.019 | -0.017 | -0.028 | -0.037 |